Led · Series B · May 2026

Founded in 2017 and based in Hong Kong, August Robotics develops a modular robotics platform that ingests project plans, localizes robots on site, plans and executes tasks autonomously, coordinates fleets and detects and rectifies errors in real time. Its current product offerings include autonomous fleets of downward-drilling robots aimed at large prefabricated construction sites and an initial use case in AI data center construction. The company also launched Lionel, an autonomous floor-marking robot fleet for exhibitions and large indoor spaces. August Robotics has commercial deployments across hyperscale construction environments in the US and Europe and launched its drilling fleets in strategic partnership with Stanley Black & Decker’s DEWALT brand. The company’s autonomy stack is applied across its drilling and other workflows. Following the $30M Series B, August Robotics intends to expand operations and accelerate development efforts.

Led · Seed · Feb 2026

ORamaVR builds CMXR, an extended-reality platform that blends artificial intelligence, medical knowledge, robotic digital twins, and real-time analytics to address training, planning, navigation, rehabilitation, and therapy in healthcare. The software runs on standard hardware and is marketed to manufacturers of medical devices and surgical robots as well as nursing schools and medical training centers. Independent clinical studies cited by the company show a 32% improvement in medical skills and an 80% reduction in errors when using the platform. ORamaVR’s neurosymbolic AI-based MAGES-SUITE has already been adopted by institutions worldwide, giving the firm early commercial traction. With the newly raised capital, the company plans to scale product development, fulfill existing commercial contracts with leading hardware manufacturers, and expand global sales. The firm also strengthened its leadership team by appointing Jan Grund Pedersen as Chief Business Officer. No revenue figures were disclosed, but the company indicates that multiple commercial agreements are in place.

Led · Equity · Oct 2025

Nutropy is a French food-tech startup that engineers animal-free casein and other dairy proteins using precision fermentation, then formulates them into B2B powdered ingredients branded as “plug-and-play” solutions for traditional dairy manufacturers. Its flagship offering, a “cheeseable milk” base, can be transformed into cheese and other dairy products that match the taste, texture and nutrition of conventional counterparts while lowering environmental impact. Led by co-founders Nathalie Rolland (CEO) and Dr. Maya Bendifallah (CSO), the company sells to food producers rather than end consumers. With fresh capital in hand, Nutropy plans to scale industrial production of casein, broaden its portfolio of dairy applications, and pursue commercial opportunities across North America, Asia and Europe. The firm has secured public support from French and European programs, including Bpifrance, to complement private investment. Financially, the company closed a €2 million pre-seed round in 2022 and has now added €7 million in new funding, bringing total known equity raised to €9 million.

Led · Seed · Sep 2025

Founded in 2021 by Robin Roumengas and Dr. David Luu, Juisci provides a mobile-first platform that uses proprietary AI trained on scientific literature to produce summaries, article recommendations, videos, podcasts and infographics. The service helps healthcare professionals combat information overload by delivering clear, reliable insights drawn from the rapidly expanding body of medical research. Juisci reports more than 200,000 users across 60 countries and 10 languages, claiming it can save clinicians up to eight hours per week. The company’s client roster exceeds 30 organisations, including Sanofi, UCB, Takeda, bioMérieux, Johnson & Johnson, Air Liquide, L’Oréal, and multiple hospitals and scientific societies. Revenue figures were not disclosed, but the firm positions itself as a partner to pharmaceutical, MedTech and healthcare institutions. With fresh capital, Juisci plans to boost R&D, scale its team and accelerate international expansion, prioritising growth in the U.S. market.

Led · Series B · Jul 2025

Numan is a UK digital healthtech company that delivers personalised, integrated care on a single platform, including clinical guidance, medication, behavioural health coaching, diagnostics and supplements. It focuses on stigmatised conditions such as obesity and testosterone deficiency and has treated over 650,000 patients across obesity management, men’s health, and diagnostics. Numan reported $90M in 2024 revenue, saw revenue more than double year-on-year, achieved profitability 18 months ago, and maintains a market-leading NPS of 68. The company plans to expand into female health and deepen patient relationships through enhanced screening and preventive care programmes. Funding will also support scaling the platform’s infrastructure, expanding marketing to reach more patients, and advancing AI-driven capabilities in a clinically responsible manner. Leadership frames the raise as a move to scale what works after strong commercial performance and high patient engagement. Numan operates a subscription service addressing men’s health issues including hair loss, gut and lung health, sexual health, and nutritional deficiencies. Its product set includes an AI-powered symptom checker, online access to medical professionals, prescription medication, at-home blood testing, and consumer health products. The company has recently launched its blood testing proposition in the UK and acquired Swedish medical science and healthcare technology company Vi-Health last year. Numan says it has grown revenues by almost three times year-on-year. It plans to launch new therapeutic areas in men’s health, expand internationally, and aims to double its headcount in 2022. The firm positions itself as a consumer health brand for men in Europe. Numan offers a subscription-based digital healthcare service for men, covering erectile dysfunction, premature ejaculation, hair loss, gut and lung health, and nutritional deficiencies. The company enables remote testing, including blood tests that do not require in-person appointments. Post-pandemic demand for remote health and behavioral support has accelerated adoption of Numan’s model. Numan is regulated by the Care Quality Commission as a registered healthcare provider. The company has expanded both organically and via two strategic acquisitions in the U.K. and Sweden to broaden its footprint. In an internal survey of 800 subscribers, 88% said Numan improved their confidence and 68% said it improved their relationships, while over half reported the pandemic gave them a more positive impression of digital healthcare. Launched almost 18 months ago, Numan joined a growing set of sites targeting men’s health. It began by promoting accessible medical remedies for erectile dysfunction and has since expanded into other areas, building a brand around pharmaceuticals on subscription. The company positions itself as providing simple and accessible solutions for men’s health and wellbeing. Numan closed a £10 million Series A to support its growth. It plans to use the funds to continue investing in technology, expand operations and grow the team. Sam Shah, former CEO of NHSX, recently joined Numan as chief medical strategy officer, and Birgir Már Ragnarsson of Novator will join the board.